Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Metabolic Brain Disease
Published in: Metabolic Brain Disease 6/2017

01-12-2017 | Original Article

Individuals with autism have higher 8-Iso-PGF2α levels than controls, but no correlation with quantitative assay of Paraoxonase 1 serum levels

Authors: Bianca Pop, Alexandru-Ștefan Niculae, Tudor Lucian Pop, Andreea Liana Răchișan

Published in: Metabolic Brain Disease | Issue 6/2017

Login to get access

Abstract

Autism spectrum disorder (ASD) represents a very large set of neurodevelopmental issues with diverse clinical outcomes. Various hypotheses have been put forth for the etiology of autism spectrum disorder, including issues pertaining to oxidative stress. In this study, we conducted measurements of serum 8-Iso-Prostaglanding F2 α (8-iso-PGF2α, which is the results of non-enzimatically mediated polyunsaturated fatty acid oxidation) in a population of individuals with autism and a control group of age and sex matched controls. A quantitative assay of Paraoxonase 1 (PON1) was conducted. Data regarding comorbidities, structural MRI scans, medication, intelligence quotient (IQ) and Childhood Autism Rating Scale scores (CARS) were also included in our study. Our results show that patients diagnosed with autism have higher levels of 8-iso-PGF2α than their neurotypical counterparts. Levels of this particular metabolite, however, do not correlate with quantitative serum levels of Paraoxonase 1, which has been shown to be altered in individuals with autism. Neither 8-iso-PGF2α nor quantitative levels of PON1 provide any meaningful correlation with clinical or neuroimaging data in this study group. Future research should focus on providing data regarding PON 1 phenotype, in addition to standard quantitative measurements, in relation to 8-iso-PGF2α as well as other clinical and structural brain findings.
Literature
Autism Spectrum Disorder, 299.00 (F84.0) (2013) In Diagnostic and statistical manual of mental disorders: DSM-5. (5th ed.). American Psychiatric Association, Washington, D.C.
Bhattacharyya T et al (2008) Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299(11):1265–1276CrossRefPubMed
Charman T, Taylor E, Drew A et al (2005) Outcome at 7 years of children diagnosed with autism at age 2: predictive validity of assessments conducted at 2 and 3 years of age and pattern of symptom change over time. J Child Psychol Psychiatry 46:500–513CrossRefPubMed
Chauhan A, Tapan A, Chauhan V (2012) Brain region-specific glutathione redox imbalance in autism. Neurochem Res 37(8):1681–1689CrossRefPubMed
Costa LG et al (2013) Modulation of paraoxonase 2 (PON2) in mouse brain by the polyphenol quercetin: a mechanism of neuroprotection? Neurochem Res 38(9):1809–1818CrossRefPubMedPubMedCentral
Damodaran LPM, Arumugam G (2011) Urinary oxidative stress markers in children with autism. Redox Rep 16(5):210–222CrossRef
Draganov DI et al (2005) Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 46(6):1239–1247CrossRefPubMed
Frustaci A, Neri M, Cesario A, Adams JB, Domenici E et al (2012) Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. Free Radic Biol Med 52:2128–2141CrossRefPubMed
Geschwind DH, Levitt P (2007) Autism spectrum disorders: developmental disconnection syndromes. Curr Opin Neurobiol 17:103–111CrossRefPubMed
Happe F, Ronald A, Plomin R (2006) Time to give up on a single explanation for autism. Nat Neurosci 9:1218–1220CrossRefPubMed
Hosmer J, David W (2004) Lemeshow S. John Wiley & Sons, Applied logistic regression
Howlin P, Goode S, Hutton J et al (2004) Adult outcome for children with autism. J Child Psychol Psychiatry 45:212–229CrossRefPubMed
Humbert R et al (1993) The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3(1):73–76CrossRefPubMed
James SJ et al (2006) Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet 141:947–956CrossRef
Jarvik GP et al (2000) Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype. Arterioscler Thromb Vasc Biol 20(11):2441–2447CrossRefPubMed
Johnson CP, Myers SM (2007) Identification and evaluation of children with autism spectrum disorders. Pediatrics 20(5):1183–1215CrossRef
Khersonsky O, Tawfik D (2005) Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44(16):6371–6382CrossRefPubMed
Li H, Liu D, Liang C. (2003) Paraoxonase gene polymorphisms, oxidative stress, and diseases. Journal of molecular medicine81.12: 766–779
Loth E, Murphy DG, Spooren W. Defining Precision Medicine Approaches to Autism Spectrum Disorders: Concepts and Challenges. Frontiers in Psychiatry, 7 (2016)
Magyar CI, Pandolfi V (2007) Factor structure evaluation of the childhood autism rating scale. J Autism Dev Disord 37:1787–1794CrossRefPubMed
Meguid NA, Dardir AA, Abdel-Raouf ER, Hashish A (2011) Evaluation of oxidative stress in autism: defective antioxidant enzymes and increased lipid peroxidation. Biol Trace Elem Res 143:58–65CrossRefPubMed
Ming X et al (2005) Increased excretion of a lipid peroxidation biomarker in autism. Prostaglandins Leukot Essent Fat Acids 73(5):379–384CrossRef
Morrow JD, Roberts LJ (1996) The isoprostanes: current knowledge and directions for future research. Biochem Pharmacol 51(1):1–9CrossRefPubMed
Morrow JD, Harris TM, Roberts LJ (1990) Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramification for measurement of eicosanoids. Anal Biochem 184:1–10CrossRefPubMed
Newschaffer CJ, Croen LA, Daniels J, Giarelli E, Grether JK, Levy SE et al (2007) The epidemiology of autism spectrum disorders. Annu Rev Public Health 28:235–258CrossRefPubMed
Ng CJ et al (2001) Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 276(48):44444–44449CrossRefPubMed
Paşca SP et al (2006) High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism. Life Sci 78(19):2244–2248CrossRefPubMed
Pecorelli A, Leoncini S, De Felice C, Signorini C, Cerrone C et al (2012) Nonprotein-bound iron and 4- hydroxynonenal protein adducts in classic autism. Brain Dev 35(2):146–154CrossRefPubMed
Qasem H, Al-Ayadhi L, Al-Ansary A (2016) Cysteinyl leukotriene correlated with 8-isoprostane levels as predictive biomarkers for sensory dysfunction in autism. Lipids Health Dis 15(130):1–10
Rossignol DA, Frye RE (2012) A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry 17:389–401CrossRefPubMed
Schopler E, Reichler RJ, DeVellis RF, Daly K (1980) Toward objective classification of childhood autism: childhood autism rating scale (CARS). J Autism Dev Disord 10:91–103CrossRefPubMed
Signorini C et al (2013) Isoprostanes and 4-hydroxy-2-nonenal: markers or mediators of disease? Focus on Rett syndrome as a model of autism spectrum disorder. Oxidative Med Cell Longev
Metadata
Title
Individuals with autism have higher 8-Iso-PGF2α levels than controls, but no correlation with quantitative assay of Paraoxonase 1 serum levels
Authors
Bianca Pop
Alexandru-Ștefan Niculae
Tudor Lucian Pop
Andreea Liana Răchișan
Publication date
01-12-2017
Publisher
Springer US
Published in
Metabolic Brain Disease / Issue 6/2017
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI
https://doi.org/10.1007/s11011-017-0083-4

Other articles of this Issue 6/2017

Metabolic Brain Disease 6/2017 Go to the issue

Original Article

Lactulose decreases neuronal activation and attenuates motor behavioral deficits in hyperammonemic rats

Original Article

Anxiolytic-like effects of α-asarone in a mouse model of chronic pain

Original Article

Total glycosides of Paeony shows Neuroprotective effects against Semen Strychni-induced neurotoxicity by recovering secretion of hormones and improving brain energy metabolism

Original Article

Clinical and molecular analysis of 6 Chinese patients with isoleucine metabolism defects: identification of 3 novel mutations in the HSD17B10 and ACAT1 gene

Original Article

Non-invasive remote ischemic postconditioning stimulates neurogenesis during the recovery phase after cerebral ischemia

Original Article

Novel biomarkers of metabolic dysfunction is autism spectrum disorder: potential for biological diagnostic markers